What did the FDA change about HRT safety

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA Drug Safety Communication, the FDA removed the boxed warning from low-dose vaginal estrogen products because updated evidence showed these products do not carry the same risks as full-dose systemic HRT. Systemic HRT warnings remained unchanged. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

What exactly the FDA changed

According to FDA.gov, the FDA removed the boxed warning from low-dose vaginal estrogen creams, tablets, and inserts. This warning had previously stated these products may raise risks of breast cancer, stroke, heart disease, blood clots, and dementia. Updated research indicated that these small-dose treatments stay mostly in the vaginal tissue and do not significantly enter the bloodstream. Based on this evidence, the FDA determined that the strong warning was no longer accurate or appropriate for these locally acting products.

Why the FDA made this change

• Very low absorption: According to FDA Drug Safety Communication, modern data show blood estrogen levels may remain in the normal postmenopausal range when using low-dose vaginal estrogen.
• No measurable increase in cancer or clot risk: According to the WHI and subsequent studies, data from thousands of women found no rise in breast cancer, heart attack, stroke, or blood clots with these low-dose vaginal products.
• Prior warning was based on full-dose pills and patches: According to FDA.gov, those risks apply to systemic HRT, not to local vaginal therapy.

What did NOT change

• Systemic HRT (pills, patches, gels, sprays) still carries the same FDA warnings about blood clot, stroke, and breast cancer risk, especially when starting after age 60 or more than 10 years past menopause. According to FDA-approved prescribing information for systemic estrogen products, these risks remain a required part of labeling.
• Progesterone remains required if systemic estrogen is used by individuals with a uterus, to protect the uterine lining, according to ACOG.

What this means for women

According to FDA.gov, low-dose vaginal estrogen products may be appropriate for many individuals using estrogen only for vaginal dryness, discomfort with intercourse, or recurrent UTIs — including many who are not candidates for systemic HRT. If you use systemic HRT for hot flashes, sleep, or mood concerns, the existing safety guidance from the FDA has not changed. All decisions about hormone therapy should be made in consultation with a qualified prescriber.